Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ropivacaine + fentanyl
- Development stage
- Phase 4
- Lead developer
- AstraZeneca
- Modality
- Small Molecules
- Administration
- Epidural
01
Overview
Ropivacaine + fentanyl is a combination medication used for epidural analgesia in various clinical settings. Ropivacaine is an amide local anesthetic that blocks sodium channels to prevent nerve impulse generation and conduction, while fentanyl is an opioid analgesic that enhances the analgesic effect. This combination provides effective pain relief with potentially fewer side effects than other combinations, particularly with reduced motor blockade compared to bupivacaine-fentanyl combinations.
- Other names
- FA + ropivacaine
02
Targets
MOR (Mu opioid receptor)NaV (Voltage-gated sodium channels)
Beyond the preview
Go deeper on ropivacaine + fentanyl.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ropivacaine + fentanyl.